Posted by Michael Wonder on 31 Mar 2022
New drug application resubmission
31 March 2022 - NDA submission for Polarean’s hyperpolarised 129Xenon gas drug device combination product
Polarean Imaging announces that the company has filed the resubmission of its new drug application with the U.S. FDA..
